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Infection with encapsulated bacteria can be prevented by vaccination with capsular polysaccharides, 
either plain or conjugated to a protein carrier. But results concerning these vaccinations raise 
several paradoxes. Polysaccharides from encapsulated bacteria are generally considered to be T-
independent antigens unable to trigger a T-dependent germinal center reaction, but strikingly, anti-
polysaccharide antibodies are often mutated in humans. Polysaccharide-protein conjugate vaccines 
are able to induce a true T-dependent memory response with a rise in antibody titers and a switch to 
high affinity-IgG antibodies in children below 2 years of age, but neither the plain nor the conjugate 
vaccine can induce memory in older infants and adults. We propose some explanations to these 
paradoxes based on our recent observation that humans display a circulating splenic marginal zone 
B cell population with a pre-diversified immunoglobulin repertoire in charge of the immune 
response to T-independent vaccines.  
 
 
The impact of diseases generated by encapsulated bacteria has been underlined in many contexts 
and it is estimated that they are responsible for millions of children’s deaths each year [1]. 
Nevertheless, when looking at the abundant literature on immune responses to encapsulated bacteria 
after vaccination by either plain or conjugated capsular polysaccharide vaccines, some paradoxes 
emerge which we would like to discuss. 
 
Paradox 1 
It is generally accepted that bacterial capsular polysaccharides (CPS) are TI antigens that trigger 
specific B cells residing in the splenic marginal zone to secrete antibodies with opsonophagocytic 
properties against these bacteria [2]. In rodents in which these responses have been mostly studied, 
immunization do not induce an extensive proliferation within B cell follicles, neither the formation 
of germinal centers, and are for most of them taken care by unmutated germline antibodies [3-5]. In 
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humans on the contrary, the splenic marginal zone contains B cells with mutated Ig receptors [6-8] 
and mutated antibodies are raised in responses to encapsulated bacteria, these mutations being 
responsible for the antibodies avidity for the immunizing antigen [9, 10]. In all species, these TI 
responses do not trigger any memory, the B cells engaged being able very rapidly to switch isotype 
and to secrete large amount of antibodies. These plasma cells can remain in the organism for 
various lengths of time, after which the response wanes out [11, 12]. To account for the presence in 
humans of mutated antibodies during a T-independent immune response that cannot normally 
trigger a cognate T-B dependent germinal center reaction, the classical explanation put forward by 
authors is that such responses are in fact taken care by bona fide memory B cells that have been 
primed by a previous encounter with the pathogen, either during an infection or by silent carriage 
[13-15]. These memory B cells would then eventually reside in the splenic marginal zone where 
they could acquire marginal zone B cell surface markers [16-18]. This explanation requires that 
during this natural priming which must have occurred in each case analyzed so far, the 
polysacharidic capsules from the pathogen are somehow linked to a protein moiety in order to drive 
the response into the classical germinal center-dependent memory B cell pathway.  
 
Paradox 2 
Children below 2 years do not respond to plain CPS vaccines but they do respond when the CPS are 
conjugated to a protein carrier (Table 1 and Box 1). Moreover these conjugate vaccines will induce 
a memory response with a rise of antibody titer after several rounds of immunization and a booster 
response several months later [21-24]. Surprisingly, in older infants and in adults, the same 
conjugate vaccine does not induce a memory response but a response similar to the one obtained 
with the plain CPS preparation [25-28], even though the response to the conjugate appears in some 
cases more robust [29-30]. 
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A proposed explanation 
We have shown that humans display a circulating marginal zone B cell population which is 
involved in TI response and which diversifies its Ig receptor in the absence of cognate T-B 
interactions. These conclusions are based on the following experimental facts: 
1) Hyper-IgM patients with either CD40L or CD40 deficiency do not have germinal centers and 
possess a population of circulating IgM+IgD+CD27+ B cells with a mutated Ig receptor, in the 
complete absence of switched memory B cells. In both types of patients the frequency of Ig 
mutations observed in these cells is similar to the one observed in controls, although the 
number of IgM+IgD+CD27+ blood cells is in general lower in the patients as compared to 
normal children. The absence of CD40 or CD40L may alter B cell development by hampering 
the network of cytokines interactions involving dendritic cells, activated T cells and natural 
killer cells. Nevertheless, the fact that these patients never display any CD27+ switched B cell 
indicate that the IgM+IgD+CD27+ B cells present are not produced in some cryptic germinal 
center structures, but rather belong to a separate population.  
2) Phenotypic analysis and gene expression profiling in normal individuals indicate that human 
splenic marginal zone B cells are, as opposed to rodents [31], recirculating in the blood. 
3)  After vaccination with a non-conjugated pneumococcal vaccine, blood and splenic 
IgM+IgD+CD27+ B cells are specifically mobilized in this T-independent response. This 
response is taken care of by B cells carrying mutated antibodies prior to immunization. Upon 
expansion of these cells in the splenic marginal zone during the week following vaccination, 
the hypermutation process is reactivated. 
4) The blood IgM+IgD+CD27+ B cell population starts to expand after birth. It is well expanded 
and mutated in children around one year of age, an age at which toddlers do not respond to T-
independent antigens, thus strongly suggesting that diversification results at this stage from a 
developmental program and not from an immune response. 
 5 
Our conclusion from these preliminary investigations is, as already proposed in our first report [32], 
that this so-called memory IgM+IgD+CD27+ B cell population, which represents 10-30% of B cells 
in blood and spleen, belonged to a different pathway of differentiation and was linked to the 
response against TI-antigens [33]. A similar conclusion was reached by R. Carsetti and her 
colleagues in a recent report, based on their study on the responding capacity asplenic or 
splenectomized patients to T-independent pneumococcal antigens [34]. 
The model we propose offers obviously another solution to paradox 1 without having to involve an 
obligatory primary infection or carriage. The B cells involved in the response are already pre-
diversified and can undergo another round of hypermutation after stimulation by the immunizing 
antigen. These B cells, which are already in a pre-activated state, do not possess any properties 
attributed to memory B cells. However, being constantly triggered by TI antigens, they could 
account for most of the so-called « natural » IgM antibodies present in the circulation [35]. 
In order to explain paradox 2 we would like to propose that before two years of age, in the absence 
of a functional splenic marginal zone, CPS vaccines conjugated to a protein carrier will trigger 
naive follicular B cells and drive them into a germinal center-dependent reaction including affinity 
maturation and memory B cell generation. After two years, the now functional splenic marginal 
zone will sequester polysaccharidic preparations from encapsulated bacteria, whether they are 
conjugated to a protein carrier or not, thus explaining why a similar marginal zone type of response 
without any memory characteristics is obtained with both the plain and the conjugated CPS 
vaccines. Strikingly, bone marrow transplanted patients, which cannot respond to pneumoccocal 
CPS until approximately 2 years after the transplant, respond to the conjugate vaccine like normal 
toddlers below 2 years by generating a clear memory response [36, 37]. Thus in both situations in 
which the splenic marginal zone is not functional, do we see an uncoupling between the response to 
the plain and the conjugated CPS preparation. 
There may be direct clinical consequences to our propositions that can be tested. Effectively, 
patients undergoing a splenectomy are usually vaccinated by the plain or the conjugated vaccines 
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prior to the operation. According to our scheme these patients should mount, like toddlers, a 
memory response if vaccinated by the conjugated vaccine after splenectomy. The same result 
should be obtained with asplenic patients. 
Moreover, having observed that the B cells engaged in these responses are already well developed 
and mutated in blood at an age at which children cannot respond to the plain CPS vaccine, and 
taking into account that it will be challenging to conjugate the serotypes of all encapsulated bacteria 
(e.g. there are 90 serotypes for Streptoccocus pneumoniae and only 11 have been conjugated at this 
moment), it is tempting to speculate that plain vaccines in conjunction with the appropriate adjuvant 
specific for these cells may be able to trigger a protective response in toddlers below 2 years. It is 
clear that such a result if possible would be a life-saving progress in underdeveloped countries. 
 
There remain many unsolved questions concerning these cells and the response against 
encapsulated bacteria. The splenic marginal zone being obviously a complex lymphoid niche, is 
there a contribution in humans, even minor, of bona fide memory B cells to TI responses? What are 
the cells that sequester CPS antigens after 2 years, whether there are in their natural or vaccine 
form? Does this occur in the splenic marginal zone or also in blood through specific DC which can 
bring them to the spleen, and what are the specific receptors involved? [38, 39] 
How and where do marginal zone B cells diversify their Ig receptor throughout life? During the first 
two years of life in infants one can study blood IgM+IgD+CD27+ B cells as they develop and 
diversify their Ig receptors, prior to any immune response. Thereafter encounter with external TI 
antigens in the mature environment of the splenic marginal zone will trigger their effector function, 
i.e. the production of antibodies What pre-activates these cells and drive their final differentiation 
remains an open question. This pre-diversification step could take place in the splenic marginal 
zone and in marginal zone-like regions in lymph nodes and Peyer’s patches [40]. It could 
alternatively occur in isolated B lymphoid follicles along the gut, as has been described for other 
species [41] (see below). A similar pre-activated stage has been described for NK T cells [42], and, 
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similarly to them, pre-activation of marginal zone B cells could be driven by self or bacterial 
commensal antigens. For both these cellular populations, NKT and marginal zone B cells which are 
intermediate between the innate and adaptive immune system, this pre-activated stage may explain 
why they react very rapidly upon challenge by external bacterial antigens [12]. 
 
Looking at other B cell immune systems 
GALT (gut-associated lymphoid tissues) species, as opposed to bone marrow species, do not use 
ongoing rearrangement in the bone marrow to generate B cell diversity. They include a large 
number of mammalian species studied today (sheep, rabbits, cattle, pigs, etc…) and have been 
named so because they generate their B cell pre-immune repertoire by post-rearrangement 
diversification processes such as hypermutation and/or gene conversion in gut-associated lymphoid 
tissues [43, 44]. This pre-diversification step is antigen-independent although gut bacterial antigens 
provide the mitotic stimuli permitting the intense proliferation of these cells in GALT follicles [45, 
46]. Moreover, in all these species there is only one window of B cell production and diversification 
that occurs during several months after birth, the peripheral B cell compartment being then installed 
for the whole life of the animal. The obvious advantage of this mode of generation of the B cell 
repertoire by gene conversion and hypermutation, which target all three CDRs, is the variety of 
specificities and affinities produced, allowing these species to also respond to T-independent 
antigens with a large range of binding capacities. 
Despite obvious differences between GALT B cells and human marginal zone B cells, our data 
imply that humans have most probably conserved for one arm of their B cell system the strategies 
used by GALT species to diversify their pre-immune repertoire. This strategy which differs from 
the one used by follicular B cells, allows the generation of a robust immune response against life 
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Figure 1. A proposed scheme for the response to PS vaccines, plain or coupled to a protein 
carrier. Round shapes represent B cells and irregular ones, cells involved in antigen capture 
(macrophages, dendritic cells,...). 
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Box 1: History 
 
“It occurred to us that if the pneumococcus polysaccharide could be combined with a foreign 
protein it should be possible to produce a conjoined carbohydrate-protein antigen capable of 
stimulating the formation of type-specific pneumococcus antibodies in the animal body. 
Provided the specificity of the original carbohydrate has not been too greatly altered either 
through chemical manipulation, or through the introduction of new molecular groupings, one 
should obtain on immunization with such a “synthetic antigen”, antibodies which would be 
identical in specific action with those produced by immunization with the intact bacterial 
cells.” 
Walter F. Goebel and Oswald T. Avery J. Exp. Med. 54, 431-436 (1931)  
 
The first conjugate vaccine was developped by Goebel and Avery [19]. In trying to 
understand how the polysaccharides of the pneumococcal capsule were involved in the 
virulence of the organism, Avery a few years later identified DNA as the support of genetic 
information, in the famous bacterial transformation experiment with Colin M. McLeod and 
Maclyn McCarty [20]. 
 
 

